Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (6902)	2/1/1999 8:34:00 PM
From: Anthony Wong	Respond to of 9523

Pfizer's Viagra Helps Impotent Diabetics, New Research Shows Bloomberg News Feb 1 1999 6:33PM ET Pfizer's Viagra Helps Impotent Diabetics, New Research Shows Chicago, Feb. 1 (Bloomberg) -- Pfizer Inc., the fourth- largest U.S. drugmaker, could benefit from company-funded research showing its Viagra drug can treat impotent diabetics. The research, published in the Journal of the American Medical Association, offers reassurance to patients with erectile dysfunction who also suffer from diabetes and want to take Viagra. Nearly 16 million Americans have diabetes, and impotence is a common problem among diabetic men. Researchers led by Marc Rendell of the Creighton Diabetes Center in Omaha, Nebraska, found that 56 percent of patients taking Viagra reported improved erections, compared to 10 percent of patients taking a placebo. In addition, 61 percent of men in the Viagra group reported they successfully had intercourse at least once, compared with 22 percent of men taking a placebo. The most common side effects among the 252 patients who completed the study were headache, indigestion and respiratory problems such as sinus congestion, the researchers said. Pfizer won approval for Viagra last year, and the drug quickly became a household name. It had sales of $411 million in its first three months on the market, making its market introduction the most successful ever. Last quarter, the drug had sales of $236 million. --Kristin Jensen in Chicago through the Princeton newsroom (609) 279-4000/gfh Story illustration: To graph Pfizer's stock activity in the past year: PFE US snap.com

To: BigKNY3 who wrote (6902)	2/2/1999 12:25:00 PM
From: Anthony Wong	Respond to of 9523

Pfizer Inc. Maintained 'Buy' at PaineWebber Bloomberg News February 2, 1999, 8:01 a.m. ET Princeton, New Jersey, Feb. 2 (Bloomberg Data) -- Pfizer Inc. (PFE US) was maintained ''buy'' by analyst Jeffrey Chaffkin at PaineWebber Inc. The 12-month target price is $156.00 per share. -- Andrew Bekoff in Princeton, New Jersey, (609)279-3652